Anticoagulants Reversal Drugs - Global Industry Outlook to 2026: The Approval of Blockbuster Drugs in Recent Years, and a Strong Pipeline, is Driving Growth

DUBLIN, April 18, 2019 /PRNewswire/ -- The "Global Anticoagulants Reversal Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 to 2026" report has been added to's offering.

The global anticoagulants reversal drugs market expected to expand at a CAGR of 15.3% from 2018 to 2026, owing to the approval of blockbuster drugs in recent years and strong pipeline driving the market.

The U.S. Food and Drug Administration has designated Andexxa (the most recently approved drug for factor Xa inhibitors) as an orphan drug and tagged under the accelerated approval process. European Medicines Agency is also positive to grant approval for andexanet alfa, with Committee for Medicinal Products for Human Use (CMPH) reviewing the application.

Idarucizumab, approved in 2015 for an antidote for dabigatran during atrial fibrillation, is currently under clinical trials for multiple conditions such as hemorrhage and stroke. Thus strong pipeline and governmental initiatives will drive the market for anticoagulant reversal drugs market.

Drugs type such as prothrombin complex concentrates, Vitamin K, desmopressin which were earlier preferred for containing emergency situation will demonstrate sluggish growth due to the launch of novel drugs with better efficacy and quicker effect. However, high prices of patented drugs would act as a growth barrier in emerging economies.

In terms of geography, North America held the largest share in the global anticoagulant reversal drugs market owing to increased approvals and increasing research and development by major pharmaceutical companies in the region. Europe also held a significant share in the global market attributable to product approvals. The growing incidence of uncontrollable bleeding episodes and usage of anticoagulants will further drive the market in North America and Europe.

The U.S. emerged as the largest country-level market due to efficient reimbursement scenario of for drugs, a high cost of the recently approved drugs and accelerated drug approval initiative by U.S. Food and Drug Administration (FDA) to drive the market.

The Asia Pacific is set to grow at the fastest rate during the forecast period, driven by rising patient population for diseases such as atrial fibrillation, strokes, and other cardiopulmonary diseases. Ongoing trials in the region will further stimulate market growth in the region.

The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Key Market Movements

    --  Strong pipeline for anticoagulant reversal drugs in North America and
        Europe to drive the market during the forecast period
    --  Growing research and development by pharmaceutical players further boost
        market growth
    --  A rising incidence of uncontrollable bleeding episodes and emergency
        situation due to the use of anticoagulants

Topics Covered

Chapter 1. Preface
1.1. Report Description
1.2. Research Scope
1.3. Research Methodology
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Anticoagulant Reversal Drugs Market Portraiture
2.2. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2017 (US$ Mn)
2.3. Global Anticoagulant Reversal Drugs Market, by Geography, 2017 (US$ Mn)

Chapter 3. Anticoagulant Reversal Drugs: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Anticoagulant Reversal Drugs Market, by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs Market, by Geography, 2016-2026 (US$ Mn)
5.1. North America Anticoagulant Reversal Drugs Market Analysis, 2016-2026
5.2. Europe Anticoagulant Reversal Drugs Market Analysis, 2016-2026
5.3. Asia Pacific Anticoagulant Reversal Drugs Market Analysis, 2016-2026
5.4. Latin America Anticoagulant Reversal Drugs Market Analysis, 2016-2026
5.5. Middle East & Africa Anticoagulant Reversal Drugs Market, 2016-2026

Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.2. Fresenius Kabi AG
6.3. Pfizer Inc.
6.4. Bausch Health Companies Inc.
6.5. Amneal Pharmaceuticals Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals Inc.
6.9. Perosphere Pharmaceuticals Inc.
6.10. Ferring Pharmaceuticals

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets